PTO/SB/08a (01-08)

Approved for use through 04/30/2008. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for Form 1449A/PTO 10/567,872 Application Number May 19, 2006 INFORMATION DISCLOSURE Filing Date Ilia Fishbein STATEMENT BY APPLICANT First Named Inventor (Use as many sheets as necessary) Art Unit 1632 Wu-Cheng Winston Shen **Examiner Name** RCHP-135US SHEET 1 of 2 Attorney Docket No.

U.S. PATENT DOCUMENTS					
	Cite No.1	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Examiner Initials*		Number - Kind Code ^{2 (If known)}			
		US-2003/0166004-A1	09-04-2003	Gyuris et al.	
		US-			
		US-		I .	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (If known)	Publication Date	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant	_
Initials*	No.1	Country Code* - Number* - Kind Code*	(MM-DD-YYYY)	Document	Figures Appear	T*
						누
						느
						L
						L
						L

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Applicant's unique citation designation number (optional).

See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Examiner Signature

³Enter Office that issued the document, by the two-letter code (WIPO Standard St.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶Applicant is to place a check mark here if English language translation is attached. The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to flie (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (01-08)

Approved for use through 04/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subs	titute for Form 1449B/PTO		Complete if Known
		Application Number	10/567,872
IN	FORMATION DISCLOSURE	Filing Date	May 19, 2006
	TATEMENT BY APPLICANT	First Named Inventor	Ilia Fishbein
•	(Use as many sheets as necessary)	Art Unit	1632
		Examiner Name	Wu-Cheng Winston Shen
	SHEET 2 of 2	Attorney Docket No.	RCHP-135US

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Rem (book, magazine, Journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
		H. MIZUGUCHI et al., "CAR- or α v integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice," Gene Therapy, June 2002, Vol. 9, No. 12, pp. 769-776.		
1110				
	_			

Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through distation if not in conformance and not

Date

considered. Include copy of this form with next communication to Applicant.

Applicant's unique citation designation number (optional).

Examiner

Applicants unique citation designation number (epitodus).

Applicants unique citation designation (epitodus).

Applicants unique citation designation (epitodus).

Applicants unique citation (epitodus).

Applic